Abediterol

Abediterol is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease, but it has never been marketed.

History

Abediterol was under development by the Spanish pharmaceutical company Almirall and reached Phase II clinical trials, but was discontinued in 2021. Its coformulation with mometasone furoate also progressed to Phase II clinical trials, but was discontinued in 2019.

Mechanism of action

Abediterol is an ultra-long-acting β₂ agonist.